Home
HelpTest ID APLB Apolipoprotein B, Plasma
Useful For
Assessment of residual risk in patients at target non high-density lipoprotein-cholesterol (HDL-C) (or low-density lipoprotein-cholesterol: LDL-C)
Follow-up studies in individuals with non-HDL-C (or LDL-C) values inconsistent with risk factors or clinical presentation
Definitive studies of cardiac risk factors in individuals with significant family histories of coronary artery disease or other increased risk factors
Confirmation of suspected abetalipoproteinemia or hypobetalipoproteinemia
Method Name
Automated Turbidimetric Immunoassay
Reporting Name
Apolipoprotein B, PSpecimen Type
Plasma EDTACollection Container/Tube: Lavender top (EDTA)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions: Centrifuge and aliquot 1 mL of plasma. Send refrigerated.
Forms: If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).
Specimen Minimum Volume
0.5 mL
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma EDTA | Refrigerated (preferred) | 8 days |
| Frozen | 60 days |
Clinical Information
Apolipoprotein B (ApoB) is the primary protein component of low-density lipoprotein (LDL). LDL contains a variable amount of cholesterol, but each LDL contains exactly 1 ApoB protein. Therefore, ApoB is a superior indicator of circulating LDL compared to LDL cholesterol (LDL-C). ApoB has been demonstrated to perform equally with LDL particles measured by nuclear magnetic resonance spectroscopy.(1)
ApoB is strongly associated with increased risk of developing cardiovascular disease (CVD) and often outperforms LDL-C at predicting risk of coronary heart disease.(2-4) Patients with acceptable non-HDL-C (or LDL-C) but elevated ApoB remain at higher risk of developing CVD; conversely, patients with acceptably low ApoB but moderate non-HDL-C or LDL-C elevations are at a reduced risk for CVD.(5,6) Finally, in 7 different placebo-controlled randomized clinical trials, on-statin reduction of ApoB was more closely related to CVD risk reduction than non-HDL-C or LDL-C.(7)
Reference Values
|
Age |
Apolipoprotein B (mg/dL) |
|
<24 months |
Not established |
|
2-17 years |
Acceptable: <90 Borderline high: 90-109 High: ≥110 |
|
>18 years |
Desirable: <90 Above Desirable: 90-99 Borderline high: 100-119 High: 120-139 Very high: ≥140 |
Day(s) Performed
Monday through Saturday; Continuously
Report Available
1 dayPerforming Laboratory
Mayo Medical Laboratories in Rochester
Test Classification
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.CPT Code Information
82172